Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2021 1
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.
Sanchez L, Rungmaitree S, Kosalaraksa P, Jantarabenjakul W, Leclercq J, Yaiprayoon Y, Midde VJ, Varghese K, Mangarule S, Noriega F. Sanchez L, et al. Among authors: mangarule s. Pediatr Infect Dis J. 2023 Aug 1;42(8):711-718. doi: 10.1097/INF.0000000000003975. Epub 2023 Apr 27. Pediatr Infect Dis J. 2023. PMID: 37257121 Free PMC article. Clinical Trial.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kaali S, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Uchiyama A, Sawe F, Schuerman L, Shrestha R, Tong T, Treanor J, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 study team. Dayan GH, et al. EClinicalMedicine. 2023 Sep 12;64:102168. doi: 10.1016/j.eclinm.2023.102168. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37936652 Free PMC article.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Dayan GH, et al. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Clinical Trial.
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.
Mangarule S, Prashanth S, Kawade A, Ravi MD, Padmavathi IV, Palkar S, Tripathi VN, Singh R, Maurya M, Mitra M, Shetty RS, Kompithra RZ, Dhaded SM, Epari V, Moureau A, Jayanth MV, Varghese K, Ravinuthala S, Kukian D, Patnaik BN, Noriega F. Mangarule S, et al. Vaccine X. 2022 Sep 13;12:100216. doi: 10.1016/j.jvacx.2022.100216. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36164460 Free PMC article.
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India.
Mangarule S, Palkar S, Mitra M, Ravi MD, Singh R, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Patnaik BN, Jordanov E, Noriega F. Mangarule S, et al. Vaccine X. 2022 Jul 2;11:100190. doi: 10.1016/j.jvacx.2022.100190. eCollection 2022 Aug. Vaccine X. 2022. PMID: 35899104 Free PMC article.
Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
Sil A, Ravi MD, Patnaik BN, Dhingra MS, Dupuy M, Gandhi DJ, Dhaded SM, Dubey AP, Kundu R, Lalwani SK, Chhatwal J, Mathew LG, Gupta M, Sharma SD, Bavdekar SB, Rout SP, Jayanth MV, D'Cor NA, Mangarule SA, Ravinuthala S, Reddy E J. Sil A, et al. Among authors: mangarule sa. Vaccine. 2017 May 19;35(22):2999-3006. doi: 10.1016/j.vaccine.2017.03.009. Epub 2017 Apr 24. Vaccine. 2017. PMID: 28449972 Free article. Clinical Trial.
Antibody Persistence Following Administration of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T and IPV Vaccines and Safety and Immunogenicity of a Booster Dose of DTwP-IPV-HB-PRP~T Administered With an MMR Vaccine in Healthy Infants in India.
Mangarule S, Siddaiah P, Kawade A, Dhati RM, Padmavathi IV, Palkar S, Tripathi V, Singh R, Palvi K, Mitra M, Shetty R, Leclercq J, Midde VJ, Varghese K, Kandukuri SR, Kukian D, Noriega F. Mangarule S, et al. Pediatr Infect Dis J. 2023 Dec 1;42(12):1128-1135. doi: 10.1097/INF.0000000000004118. Epub 2023 Oct 13. Pediatr Infect Dis J. 2023. PMID: 37851978